Cargando…

Extracorporeal Membrane Oxygenation in Congenital Heart Disease

Mechanical circulatory support (MCS) is a key therapy in the management of patients with severe cardiac disease or respiratory failure. There are two major forms of MCS commonly employed in the pediatric population—extracorporeal membrane oxygenation (ECMO) and ventricular assist device (VAD). These...

Descripción completa

Detalles Bibliográficos
Autores principales: Perry, Tanya, Brown, Tyler, Misfeldt, Andrew, Lehenbauer, David, Cooper, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947570/
https://www.ncbi.nlm.nih.gov/pubmed/35327752
http://dx.doi.org/10.3390/children9030380
_version_ 1784674471308689408
author Perry, Tanya
Brown, Tyler
Misfeldt, Andrew
Lehenbauer, David
Cooper, David S.
author_facet Perry, Tanya
Brown, Tyler
Misfeldt, Andrew
Lehenbauer, David
Cooper, David S.
author_sort Perry, Tanya
collection PubMed
description Mechanical circulatory support (MCS) is a key therapy in the management of patients with severe cardiac disease or respiratory failure. There are two major forms of MCS commonly employed in the pediatric population—extracorporeal membrane oxygenation (ECMO) and ventricular assist device (VAD). These modalities have overlapping but distinct roles in the management of pediatric patients with severe cardiopulmonary compromise. The use of ECMO to provide circulatory support arose from the development of the first membrane oxygenator by George Clowes in 1957, and subsequent incorporation into pediatric cardiopulmonary bypass (CPB) by Dorson and colleagues. The first successful application of ECMO in children with congenital heart disease undergoing cardiac surgery was reported by Baffes et al. in 1970. For the ensuing nearly two decades, ECMO was performed sparingly and only in specialized centers with varying degrees of success. The formation of the Extracorporeal Life Support Organization (ELSO) in 1989 allowed for the collation of ECMO-related data across multiple centers for the first time. This facilitated development of consensus guidelines for the use of ECMO in various populations. Coupled with improving ECMO technology, these advances resulted in significant improvements in ECMO utilization, morbidity, and mortality. This article will review the use of ECMO in children with congenital heart disease.
format Online
Article
Text
id pubmed-8947570
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89475702022-03-25 Extracorporeal Membrane Oxygenation in Congenital Heart Disease Perry, Tanya Brown, Tyler Misfeldt, Andrew Lehenbauer, David Cooper, David S. Children (Basel) Review Mechanical circulatory support (MCS) is a key therapy in the management of patients with severe cardiac disease or respiratory failure. There are two major forms of MCS commonly employed in the pediatric population—extracorporeal membrane oxygenation (ECMO) and ventricular assist device (VAD). These modalities have overlapping but distinct roles in the management of pediatric patients with severe cardiopulmonary compromise. The use of ECMO to provide circulatory support arose from the development of the first membrane oxygenator by George Clowes in 1957, and subsequent incorporation into pediatric cardiopulmonary bypass (CPB) by Dorson and colleagues. The first successful application of ECMO in children with congenital heart disease undergoing cardiac surgery was reported by Baffes et al. in 1970. For the ensuing nearly two decades, ECMO was performed sparingly and only in specialized centers with varying degrees of success. The formation of the Extracorporeal Life Support Organization (ELSO) in 1989 allowed for the collation of ECMO-related data across multiple centers for the first time. This facilitated development of consensus guidelines for the use of ECMO in various populations. Coupled with improving ECMO technology, these advances resulted in significant improvements in ECMO utilization, morbidity, and mortality. This article will review the use of ECMO in children with congenital heart disease. MDPI 2022-03-09 /pmc/articles/PMC8947570/ /pubmed/35327752 http://dx.doi.org/10.3390/children9030380 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Perry, Tanya
Brown, Tyler
Misfeldt, Andrew
Lehenbauer, David
Cooper, David S.
Extracorporeal Membrane Oxygenation in Congenital Heart Disease
title Extracorporeal Membrane Oxygenation in Congenital Heart Disease
title_full Extracorporeal Membrane Oxygenation in Congenital Heart Disease
title_fullStr Extracorporeal Membrane Oxygenation in Congenital Heart Disease
title_full_unstemmed Extracorporeal Membrane Oxygenation in Congenital Heart Disease
title_short Extracorporeal Membrane Oxygenation in Congenital Heart Disease
title_sort extracorporeal membrane oxygenation in congenital heart disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947570/
https://www.ncbi.nlm.nih.gov/pubmed/35327752
http://dx.doi.org/10.3390/children9030380
work_keys_str_mv AT perrytanya extracorporealmembraneoxygenationincongenitalheartdisease
AT browntyler extracorporealmembraneoxygenationincongenitalheartdisease
AT misfeldtandrew extracorporealmembraneoxygenationincongenitalheartdisease
AT lehenbauerdavid extracorporealmembraneoxygenationincongenitalheartdisease
AT cooperdavids extracorporealmembraneoxygenationincongenitalheartdisease